Edition:
India

Michael Erman

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

18 May 2018

FDA names drugmakers potentially acting to delay cheap generics

The U.S. Food and Drug Administration on Thursday listed a number of drugmakers it said could be improperly blocking access to their medicines in order to delay generic competition.

15 May 2018

U.S. to consider expanding Medicare drug price negotiation

WASHINGTON/NEW YORK The Trump administration is considering expanding Medicare's ability to negotiate the cost of drugs by giving private payers a role in setting the price of medicines administered in hospitals and doctors' offices, Health and Human Services Secretary Alex Azar said on Monday.

10 May 2018

FDA says Mylan's EpiPen is in shortage in U.S.

U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment. | Video

09 May 2018

FDA says Mylan's EpiPen is in shortage in U.S.

U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment. | Video

09 May 2018

Mylan says U.S. customers may have trouble getting EpiPens

NEW YORK Mylan NV said on Tuesday that U.S. consumers may have difficulty getting EpiPen prescriptions filled after manufacturing problems constrained supply, but the drugmaker did not say there was a shortage of its emergency allergy treatment. | Video

08 May 2018

Valeant tries to leave the past behind with name change, shares surge

Valeant Pharmaceuticals International Inc said on Tuesday it will change its name to Bausch Health Companies Inc as it seeks to distance itself from a series of scandals and accounting issues under the drug company's previous management.

03 May 2018

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

01 May 2018

Keytruda sales power Merck to quarterly beat

Drugmaker Merck & Co reported better-than-expected first-quarter earnings on Tuesday, helped by a more than 150 percent rise in sales of blockbuster cancer drug Keytruda. | Video

01 May 2018

Allergan CEO opposes fundamental shift in strategy, shares fall

Allergan Plc's chief executive on Monday said he was opposed to fundamental changes to the drug company's business strategy, even as its board considers drastic moves like splitting the company, selling off assets or doing deals to turn around a steep drop in its share price.

27 Apr 2018

Allergan migraine drug succeeds in second late-stage trial

NEW YORK Allergan Plc on Friday announced positive results from a second Phase III trial for the 50 milligram dose of its drug for acute migraine, reproducing results from the previous trial.

Markets

  • Asia
  • U.S.
  • Europe
  • Sectors
Stock Search
Sensex 34,848.30 -300.82 -0.86%
Nikkei 22,930.36 + 91.99 +0.40%
Hang Seng 31,047.91 + 105.76 +0.34%
EUR/INR 80.052 +0.00%
USD/INR 67.985 +0.00%
GBP/INR 91.610 +0.03%
Gold 1,289.60 +1.40 +0.11%
Oil 72.04 +0.76 +1.07%
Corn 404.50 +2.00 +0.50%